Skip to product information
1 of 1

PCSK9 Recombinant Rabbit mAb (SDT-424-252)

PCSK9 Recombinant Rabbit mAb (SDT-424-252)

Catalog Number: S0B3245 Application: ELISA Reactivity: Human Conjugation: Unconjugated Brand: Starter
Price:
Regular price $835 USD
Regular price Sale price $835 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Synonyms Neural apoptosis-regulated convertase 1 (NARC-1); Proprotein convertase 9 (PC9); Subtilisin/kexin-like protease PC9
Immunogen Recombinant Protein
Accession Q8NBP7
Clone Number SDT-424-252
Antibody Type Recombinant mAb
Isotype IgG
Application Sandwich ELISA
Reactivity Hu
Cross Reactivity Does not recognize CHI3L1
Purification Protein A
Concentration 2 mg/ml
Purity >95% by HPLC
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

Na-citrate, pH 6.0, 0.03% Proclin 300

Stability & Storage

12 months from date of receipt, 2 to 8 °C as supplied

Dilution


application dilution species
Sandwich ELISA N/A

Background

PCSK9 is ubiquitously expressed in many tissues and cell types. PCSK9 binds to and degrades the receptor for low-density lipoprotein particles (LDL), which typically transport 3,000 to 6,000 fat molecules (including cholesterol) per particle, within extracellular fluid. The LDL receptor (LDLR), on liver and other cell membranes, binds and initiates ingestion of LDL-particles from extracellular fluid into cells and targets the complex to lysosomes for destruction. If PCSK9 is blocked, the LDL-LDLR complex separates during trafficking, with the LDL digested in the lysosome, but the LDLRs instead recycled back to the cell surface and so able to remove additional LDL-particles from the extracellular fluid. Therefore, blocking PCSK9 can lower blood LDL-particle concentrations. PCSK9 has medical importance because it acts in lipoprotein homeostasis. Agents that block PCSK9 can lower LDL particle concentrations. The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated. PCSK9 inhibitors are promising therapeutics for the treatment of people who exhibit statin intolerance, or as a way to bypass frequent dosage of statins for higher LDL concentration reduction. So, measurement of plasma PCSK9 level will be more useful for monitoring treatment effect.

Picture

Paired Recommendations

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)